News - Page 78 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

Post published:November 17, 2022
Post category:Press Release

Read more about the article FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH

FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH

Post published:November 17, 2022
Post category:Press Release

Read more about the article Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market

Post published:November 17, 2022
Post category:Press Release

Read more about the article Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics (GIPSE)

Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics (GIPSE)

Post published:November 14, 2022
Post category:Interview

Read more about the article MindMed to Participate in the Jefferies London Healthcare Conference

MindMed to Participate in the Jefferies London Healthcare Conference

Post published:November 11, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of Oregon Opt-out; Sensorium Closes $30m Series A

Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of Oregon Opt-out; Sensorium Closes $30m Series A

Post published:November 11, 2022
Post category:Psychedelic Bulletin

Read more about the article FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Post published:November 10, 2022
Post category:Press Release

Read more about the article atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update

Post published:November 10, 2022
Post category:Press Release

Read more about the article Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET

Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET

Post published:November 7, 2022
Post category:Press Release

Read more about the article MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update

MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update

Post published:November 5, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.